# Evotec Announces Second FDA IND Acceptance in Bristol Myers Partnership

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/61255
Published: 2026-11-19T10:32:13.000Z
Updated: 2026-11-19T10:32:13.000Z
Section: Business

> The Nov. 19 acceptance advances the strategic protein degradation partnership; the candidate was not identified.

Evotec announced that its strategic protein degradation partnership with Bristol Myers Squibb received a second Investigational New Drug (IND) acceptance from the U.S. Food and Drug Administration on Nov. 19, 2026.


